2014 American Society of Hematology (ASH) Annual Meeting Conference Highlights in Chronic Myelogenous Leukemia
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: December 22, 2014
Expiration Date: December 22, 2015
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this educational activity, clinical experts discuss key findings relative to new and emerging treatments for chronic myelogenous leukemia (CML) from the 2014 ASH Meeting. Each module will focus on the latest data, on what the data means in the clinical setting, and how clinicians may effectively incorporate this information to improve patient care, and ultimately, patient outcomes.
The target audience for this accredited activity is hematologists, oncologists, and associated multidisciplinary clinical specialists who provide care to patients with CML.
Upon completion of this educational activity, participants should be able to:
- Assess the latest data and research concerning treatment selection in CML, focusing on key elements of efficacy, side-effect management, and clinical trial limitations
- Summarize new advances and approaches to monitoring for ongoing treatment efficacy, and improving patient adherence to medication regimens in CML
- Outline new and emerging data concerning treatment resistance in CML, and new therapeutic strategies for treating patients with the T315I mutation
- Recognize specific clinical unmet needs of CML patients and trials seeking to address those needs, such as those seeking reliable tests which can differentiate between patients that can safely discontinue therapy from those who must continue therapy
- Propose appropriate changes in practice based on clinical trial findings
|Jorge E. Cortes, MD|
|Abstract #152:||Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180056)|
|Abstract #3135:||Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial|
|Abstract #4552:||Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials|
|Abstract #519:||Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CPCML)|
|Abstract #4535:||Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)|
|Stuart L. Goldberg, MD|
|Abstract #811:||Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group (FILMC)|
|Abstract #151:||Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study|
|Abstract #812:||Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells|
|Abstract #813:||The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis|
|Abstract #1816:||Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard- Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib|
|Abstract #518:||Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib|
|Abstract #3153:||High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib|
|Abstract #4546:||Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients|
|Abstract #738:||What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?|
|Michael J. Mauro, MD|
|Abstract #3151:||Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)|
|Abstract #1796:||Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update|
|Abstract #4541:||Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd|
|Abstract #4532:||Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party|
|Abstract #3141:||Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis|
|Abstract #4551:||Comparative Efficacy Among 3rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors|
|Abstract #4559:||Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study|
|Jerald P. Radich, MD|
|Abstract #1807:||BCR-ABL Testing Frequency Lower Than NCCN Recommendations in Lab Network Review of CML Patients|
|Abstract #517:||Spirit 2: An NCRI Randomized Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML|
|Abstract #4534:||The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program|
|Abstract #3142:||The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study|
|Abstract #1795:||A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study|
Instructions for Participation and Credit
This activity is eligible for credit through December 22, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Jorge Eduardo Cortes, MD
Professor of Medicine and Deputy Chair
Chief of the CML Section
Department of Leukemia
The University of Texas, MD Anderson Cancer Center
Dr. Jorge Cortes received his medical degree from Faculty of Medicine of the National Autonomous University of Mexico along with postgraduate training at The National Institute of Medical Sciences and Nutrition Salvador Zubirán. He also completed a hematology fellowship at The University of Texas Health Science Center at Houston, and a hematology/oncology fellowship at The University of Texas, MD Anderson Cancer Center. Dr. Cortes is professor of medicine and deputy chair, and is also the chief of the CML Section in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center.
Dr. Cortes has authored hundreds of peer-reviewed articles, abstracts, book chapters, and medical publications. He is editor-in-chief of Clinical Leukemia, and Current Malignant Hematology Reports, and is on the editorial board of Clinical Cancer Research, Leukemia, and Journal of Clinical Oncology. In addition, Dr. Cortes serves on the Board of Directors for The Leukemia & Lymphoma Society. His clinical interests focus on new drug development and the management of patients with acute and chronic leukemia.
Stuart L. Goldberg, MD
Chief, Division of Leukemia
John Theurer Cancer Center
Hackensack, New Jersey
Dr. Stuart Goldberg received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center. He completed his internal medicine residency and his hematology-oncology fellowship at George Washington University Medical Center. He also completed a bone marrow transplantation fellowship at Fred Hutchinson Cancer Research Center. Dr. Goldberg is chief, Division of Leukemia, John Theurer Cancer Center in Hackensack, New Jersey.
Dr. Goldberg specializes in medical oncology and leukemia, and is board certified in medical oncology, hematology and internal medicine. He is a member of the American College of Physicians, American Society of Blood and Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Southwest Oncology Group, and the Myelodysplastic Foundation, among others. Dr. Goldberg specializes in treating all types of leukemia and myelodysplastic syndromes with a variety of treatment modalities, including chemotherapy and stem cell transplantation.
Michael J. Mauro, MD
Professor of Medicine
Leader, Myeloproliferative Neoplasms Program
Memorial Sloan-Kettering Cancer Center
New York, New York
Dr. Michael Mauro received his medical degree from Dartmouth Medical School and completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. He is professor of medicine and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Mauro has practiced as a board-certified hematologist for the past 15 years. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years. There he directed the chronic myeloid leukemia (CML) clinical trial program and was involved in the early development and sentinel clinical studies of targeted therapy for CML.
Dr. Mauro’s clinical expertise is in treating patients with CML as well as other myeloproliferative disorders including myelofibrosis, polycythemia, and thrombocytosis, as well as less common conditions such as eosinophilic and mast cell disorders. His research interests include optimizing therapy response in CML, late and emerging side effects of kinase inhibitors, and decision-making amongst therapies for CML and other myeloproliferative neoplasms. Dr. Mauro’s patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with his patients and their referring providers to personalize recommendations and monitoring given the chronic nature of the disorders he treats.
Jerald P. Radich, MD
Professor of Medicine
University of Washington School of Medicine
Dr. Jerald Radich received his medical degree from the University of California School of Medicine, Davis. He was an intern and resident in internal medicine at University of Washington Affiliated Hospitals, chief medical resident at Veterans Administration Medical Center Hospitals, Seattle, and a fellow in medical oncology at University of Washington and the Fred Hutchinson Cancer. Dr. Radich is professor of medicine at University of Washington School of Medicine. He is director of the Research Trials Office as well as a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. In addition, Dr. Radich co-chairs the Leukemia Biology for the Southwest Oncology Group (SWOG) and the NCI/Cooperative Group Leukemia Steering Committees, and is on the National Cancer Care Network and EuroLeukemiaNet CML committees. His main research interests include the genetics of leukemia and development of modern molecular biology techniques for early detection of leukemia.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-041-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour(s). Program Number: 14-041-359
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jorge Cortes has received honoraria as a consultant and grant support related to research activities from ARIAD Pharmaceuticals, Bristol-Myers Squibb, Novartis AG, and Pfizer Inc., Inc., in addition to grant support related to research activities from Teva Pharmaceuticals.
Dr. Stuart Goldberg has received honoraria related to formal advisory activities from ARIAD Pharmaceuticals, Inc. and Novartis AG, and speakers’ bureau activities from ARIAD, Bristol-Myers Squibb Company, and Novartis. He has received grant support related to research activities from Bristol-Myers Squibb, Novartis, and Pfizer Inc.
Dr. Michael Mauro has received honoraria as a consultant from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc.
Dr. Jerald Radich has received honoraria as a consultant from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb, Incyte Corporation, and Novartis AG. He has received grant support related to research activities from Novartis.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Cortes, Goldberg, Mauro, and Radich have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Cortes, Goldberg, Mauro, and Radich have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis, and Teva Pharmaceuticals.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.